Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 08/31
(Values in U.S. thousands)
| 11-2025 | 08-2025 | 05-2025 | 02-2025 | 11-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,598 | -11,911 | -9,214 | -5,424 | -2,707 |
| Depreciation Amortization | 17 | 88 | 66 | 36 | 33 |
| Accounts receivable | 280 | -214 | -204 | -177 | -110 |
| Other Working Capital | 490 | 196 | 520 | 864 | -177 |
| Other Operating Activity | -174 | 1,392 | 1,025 | 478 | 234 |
| Operating Cash Flow | $-984 | $-10,450 | $-7,808 | $-4,224 | $-2,726 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | -143 | N/A | N/A | N/A |
| PPE Investments | N/A | -25 | -25 | -25 | -25 |
| Purchase Sale Intangibles | -5 | -75 | -61 | -41 | -13 |
| Other Investing Activity | -5 | -75 | -61 | -41 | -13 |
| Investing Cash Flow | $-5 | $-243 | $-85 | $-66 | $-38 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 3,474 | 6,046 | 6,046 | 4,357 | 4,345 |
| Financing Cash Flow | $3,474 | $6,046 | $6,046 | $4,357 | $4,345 |
| Exchange Rate Effect | -6 | -51 | -61 | -98 | -3 |
| Beginning Cash Position | 1,802 | 6,500 | 6,500 | 6,500 | 6,500 |
| End Cash Position | 4,281 | 1,802 | 4,592 | 6,469 | 8,078 |
| Net Cash Flow | $2,479 | $-4,698 | $-1,908 | $-31 | $1,578 |
| Free Cash Flow | |||||
| Operating Cash Flow | -984 | -10,450 | -7,808 | -4,224 | -2,726 |
| Capital Expenditure | N/A | -25 | -25 | -25 | -25 |
| Free Cash Flow | -984 | -10,475 | -7,833 | -4,249 | -2,751 |